Cargando…

Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19

Detalles Bibliográficos
Autor principal:	Whitley, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693684/ https://www.ncbi.nlm.nih.gov/pubmed/34914869 http://dx.doi.org/10.1056/NEJMe2117814

Ejemplares similares

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir for COVID-19
Publicado: (2022)

Concise two-step chemical synthesis of molnupiravir
por: Pereira, Vinícius R. D., et al.
Publicado: (2022)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

Steps towards COVID-19 suppression
por: Okano, Hideyuki, et al.
Publicado: (2020)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
por: Imran, Mohd., et al.
Publicado: (2021)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2023)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Editorial: Persistent endeavors for the enhancement of dissolution and oral bioavailability
por: Wu, Wei, et al.
Publicado: (2019)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

First steps towards diagnosing long COVID
por: eBioMedicine
Publicado: (2022)

RdRp inhibitors and COVID-19: Is molnupiravir a good option?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2022)

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis
por: Gopalsamuthiram, Vijayagopal, et al.
Publicado: (2021)

First Steps toward Personalized Therapies for ABCA3 Deficiency
por: Wambach, Jennifer A., et al.
Publicado: (2022)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
por: Karniadakis, Ioannis, et al.
Publicado: (2023)

Comorbidity Burden in Patients with Covid-19 Treated with Molnupiravir in the United States
por: Prajapati, Girish, et al.
Publicado: (2022)

Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
por: Xie, Yan, et al.
Publicado: (2023)

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
por: Guermazi, Dorra, et al.
Publicado: (2023)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2023)

One-step self-assembled nanomicelles for improving the oral bioavailability of nimodipine
por: Luo, Jing-Wen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_es4qeec9jojq4tavpr0pvhu08i